The risk factors and clinical outcomes in hepatitis B seropositive and seronegative renal transplant patients

Conclusion: Individuals, independent of HBsAg status, had similar prognosis in terms of patient and graft survival, acute rejection rate, and cancer development. The absence of either pre-transplant anti-HBV medication or lifelong antiviral therapy was significantly associated with an increased risk of HBV reactivation.PMID:38498992 | DOI:10.1159/000538231

Source: American Journal of Nephrology - March 18, 2024 Category: Urology & Nephrology Authors: Yu-Lien Tsai Meng-Hsuan Chung Niang-Cheng Lin Cheng-Yen Chen Yao-Ping Lin Ming-Tsun Tsai Hsin-Lin Tsai Yee-An Chen Shuo-Ming Ou Chi-Jen Chu Tsai-Hung Wu Chang-Youh Tsai Source Type: research